Form 4: BridgeBio Pharma Director Randal W. Scott Sells Shares Under 10b5-1 Plan

Director Randal W. Scott sold BridgeBio Pharma shares on June 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Randal W. Scott, a director of BridgeBio Pharma, Inc. (BBIO), reported the sale of common stock on June 3rd and 4th, 2024.
• The sales were executed under a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
• On June 3, 2024, 800 shares were sold at a weighted average price of $28.6844, with prices ranging from $28.31 to $29.24 per share.
• An additional 200 shares were sold on June 3, 2024, at a weighted average price of $29.475, with prices ranging from $29.44 to $29.55 per share.
• On June 4, 2024, 1,500 shares were sold at a price of $31.3 per share.
• Following these transactions, Scott directly owns 5,000 shares and indirectly owns 4,000 shares through Thinking Bench Capital LLC.
• The report was filed on June 5, 2024, by Brian C. Stephenson, Attorney-in-Fact.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of pre-arranged trading plans to avoid accusations of trading on material non-public information. The market typically assesses the volume and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• Shareholders may interpret insider sales as a lack of confidence, although sales under 10b5-1 plans are generally viewed as less concerning.

Key Dates